Home / Market News / $ALNY
fiscal.ai Corporate Catalyst Impact 65/100 ● negative

RBC Cuts Price Target on Alnylam Pharmaceuticals to $280

Oct 30, 2026, 11:36 AM UTC · Primary ticker $ALNY

RBC has lowered its price target for Alnylam Pharmaceuticals to $280 from $345, while reiterating an Outperform rating. This adjustment follows the company's third-quarter financial results, suggesting a re-evaluation of future growth prospects or valuation metrics by the analyst.

RBC's decision to cut Alnylam Pharmaceuticals' price target from $345 to $280, despite maintaining an 'Outperform' rating, indicates a revised outlook on the company's valuation. This adjustment likely stems from the company's recent third-quarter financial results, which may have presented a more conservative growth trajectory or introduced new valuation considerations for the analyst. For traders, this could lead to short-term downward pressure on ALNY shares as the market digests the lower price target, even with the continued positive rating. The long-term implications depend on whether the market views this as a temporary recalibration or a sign of underlying challenges, but the maintained 'Outperform' suggests RBC still sees upside potential from the current share price.

$ALNY negative Price target cut by analyst
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.